<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422812</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-001-202</org_study_id>
    <nct_id>NCT00422812</nct_id>
  </id_info>
  <brief_title>Staccato Prochlorperazine in Migraine (Out Patient)</brief_title>
  <official_title>A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Single Dose, Efficacy and Safety Outpatient Study of StaccatoTM Prochlorperazine for Inhalation in Patients With Migraine Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Staccato Prochlorperazine is being developed to treat patients suffering from acute migraine
      headaches. In October 2005, we completed a 75 patient, multi-center, double-blind
      placebo-controlled Phase 2A clinical trial in patients suffering from moderate to severe
      acute migraine headaches. This Phase 2B clinical trial of Staccato Prochlorperazine has been
      initiated to assess the efficacy and safety in outpatients with migraine headache with or
      without aura.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache Pain Relief at 2 hr</measure>
    <time_frame>2 hr post-dose</time_frame>
    <description>Headache pain relief at 2 hr post-dose by IHS Definition (none=0 or mild=1),</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responders, Pain-Free at 2 Hours</measure>
    <time_frame>2 hours</time_frame>
    <description>Percentage of Responders, Pain-Free, by Treatment Group over Time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival of Headache Pain Relief</measure>
    <time_frame>0 to 4 hours</time_frame>
    <description>Survival for time to the first successful headache pain relief by Pain-IHS definition over the 0 to 4 hr period by treatment assigned. Pairwise comparisons were made for each of the 3 active doses to placebo. Survival Analysis (Kaplan-Meyer) was included to evaluate treatment efficacy over the 0 to 4 hr period. All tests were 2-sided with a p-value at Î±=0.05.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Migraine Headache</condition>
  <condition>Aura</condition>
  <arm_group>
    <arm_group_label>Inhaled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled Staccato Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled PCZ 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato Prochlorperazine 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled PCZ 7.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato Prochlorperazine 7.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled PCZ 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Staccato Prochlorperazine 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Placebo</intervention_name>
    <description>Inhaled Staccato Placebo</description>
    <arm_group_label>Inhaled Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled PCZ 5 mg</intervention_name>
    <description>Inhaled Staccato Prochlorperazine 5 mg</description>
    <arm_group_label>Inhaled PCZ 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled PCZ 7.5 mg</intervention_name>
    <description>Inhaled Staccato Prochlorperazine 7.5 mg</description>
    <arm_group_label>Inhaled PCZ 7.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled PCZ 10 mg</intervention_name>
    <description>Inhaled Staccato Prochlorperazine 10 mg</description>
    <arm_group_label>Inhaled PCZ 10 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients between the ages of 18 to 70 years, inclusive.

          2. Patients who have migraine headache with or without aura (diagnosis according to
             International Headache Society guidelines) for at least 6 months.

          3. Patients who have a history of migraine and have had at least 3 migraine attacks in
             the last 3 month period (but not more than 8 migraine attacks per month). Current and
             past migraine medication history must be recorded.

          4. Patients who agree to: not use the study drug within 72 hr of a prior migraine attack,
             and to use the investigational medication when they have a pain rating of Moderate or
             Severe (on a None, Mild, Moderate or Severe Scale) prior to dosing.

          5. Patients who speak, read, and understand English sufficiently well and are willing and
             able to provide written informed consent on an IRB approved form prior to the
             initiation of any study procedures.

          6. Patients who are willing and able comply with the study schedule and study
             requirements, and agree to return to the clinic within 5 working days of use of the
             investigational treatment.

          7. Patients who are in good general health prior to study participation as determined by
             a detailed medical history, physical examination, 12-lead ECG, blood chemistry
             profile, hematology, urinalysis and in the opinion of the Principal Investigator.

          8. Female participants (if of child-bearing potential and sexually active) and male
             participants (if sexually active with a partner of child-bearing potential) who agree
             to use a medically acceptable and effective birth control method throughout the study
             and for one week following the end of the study. Medically acceptable methods of
             contraception that may be used by the participant and/or his/her partner include
             abstinence, birth control pills or patches, diaphragm with spermicide, intrauterine
             device (IUD), condom with foam or spermicide, vaginal spermicidal suppository,
             surgical sterilization and progestin implant or injection. Prohibited methods include:
             the rhythm method, withdrawal, condoms alone, or diaphragm alone.

        Exclusion Criteria:

          1. Patients who are currently taking tricyclic antidepressants, valproate, divalproex,
             barbitals, thiazolidinediones, phenothiazines, benzodiazepines, lithium or any hepatic
             toxic drugs must be excluded.

          2. Patients who are currently taking medications that prolong the QT/QTc interval (see
             Appendix 4) must be excluded.

          3. Patients with a history of contraindications to anticholinergics (bowel obstruction,
             urinary retention, acute glaucoma) must be excluded.

          4. Patients with a history of allergy or intolerance to phenothiazines and related drugs
             (prochlorperazine, chlorpromazine, promethazine, mesoridazine, thioridazine,
             fluphenazine, perphenazine) must be excluded.

          5. Patients with a history of extra-pyramidal disorders, movement disorders, neuroleptic
             malignant syndrome, or major affective disorder must be excluded.

          6. Female patients who have a positive pregnancy test at screening or are breastfeeding
             must be excluded.

          7. Patients who have a history within the past year of drug or alcohol dependence or
             abuse as defined by DSM-4 must be excluded.

          8. Patients who have a history of pheochromocytoma, seizure disorder or Parkinson's
             disease must be excluded.

          9. Patients who have a history of syncope, unstable angina, myocardial infarction (within
             6 mos), congestive heart failure, or transient ischemic attack must be excluded.

         10. Patients who have a history of a major neurological disorder other than migraine
             (subarachnoidal bleeding, stroke, brain tumor) must be excluded.

         11. Patients who have any other disease(s), by history, physical examination, or
             laboratory abnormalities (ALT or AST &gt; 2-fold the upper limit of normal, Bilirubin &gt;
             1.5 mg/dL, or creatinine &gt; 1.8 mg/dL) or that in the investigator's opinion, would
             present undue risk to the patient or may confound the interpretation of study results
             must be excluded.

         12. Patients who have a history of asthma or chronic obstructive lung disease should be
             excluded.

         13. Patients who have received an investigational drug within 30 days prior to the
             Screening Visit must be excluded.

         14. Patients who have a history of risk factors for Torsade de Pointes (e.g., heart
             failure, hypokalemia, family history of Long QT Syndrome) must be excluded.

         15. Patients who have a marked prolongation of QT/QTc interval (e.g., demonstration of a
             QT interval &gt;450 ms on screening ECG) must be excluded.

         16. Patients who are considered by the investigator, for any reason, to be an unsuitable
             candidate for receiving prochlorperazine, or unable to use the inhalation device, must
             be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel A Spyker, PhD, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alexza Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Headache Clinic</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Medical Clinic for Headache</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurological Research Institute of East Bay</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mile High Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218-1110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Neurologists of Southern Connecticut PC</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Headache Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The New England Center for Headache</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Clinical</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Neurological Center</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diamond Headache Clinic</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614-1726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medvadis</name>
      <address>
        <city>Wellesley Hills</city>
        <state>Massachusetts</state>
        <zip>02481-2106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Regional Headache Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Michigan Head-Pain and Neurological Institute</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104.5199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Headache Care Center Primary Care Network, INC</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkind Headache Center</name>
      <address>
        <city>Mount Vernon</city>
        <state>New York</state>
        <zip>10050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Headache Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Neurological Associates, PC</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmQuest</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research Associates</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinExcel Research</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Neurologists/OUHSC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Headache Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2007</study_first_submitted>
  <study_first_submitted_qc>January 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2007</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>June 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2018</results_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine, Staccato Prochlorperazine</keyword>
  <keyword>Migraine headache with or without aura.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prochlorperazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Placebo</title>
          <description>Inhaled Staccato Placebo
Inhaled Placebo: Inhaled Staccato Placebo</description>
        </group>
        <group group_id="P2">
          <title>Inhaled PCZ 5 mg</title>
          <description>Inhaled Staccato Prochlorperazine 5 mg
Inhaled PCZ 5 mg: Inhaled Staccato Prochlorperazine 5 mg</description>
        </group>
        <group group_id="P3">
          <title>Inhaled PCZ 7.5 mg</title>
          <description>Inhaled Staccato Prochlorperazine 7.5 mg
Inhaled PCZ 7.5 mg: Inhaled Staccato Prochlorperazine 7.5 mg</description>
        </group>
        <group group_id="P4">
          <title>Inhaled PCZ 10 mg</title>
          <description>Inhaled Staccato Prochlorperazine 10 mg
Inhaled PCZ 10 mg: Inhaled Staccato Prochlorperazine 10 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="104"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="91"/>
                <participants group_id="P4" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Placebo</title>
          <description>Inhaled Staccato Placebo
Inhaled Placebo: Inhaled Staccato Placebo</description>
        </group>
        <group group_id="B2">
          <title>Inhaled PCZ 5 mg</title>
          <description>Inhaled Staccato Prochlorperazine 5 mg
Inhaled PCZ 5 mg: Inhaled Staccato Prochlorperazine 5 mg</description>
        </group>
        <group group_id="B3">
          <title>Inhaled PCZ 7.5 mg</title>
          <description>Inhaled Staccato Prochlorperazine 7.5 mg
Inhaled PCZ 7.5 mg: Inhaled Staccato Prochlorperazine 7.5 mg</description>
        </group>
        <group group_id="B4">
          <title>Inhaled PCZ 10 mg</title>
          <description>Inhaled Staccato Prochlorperazine 10 mg
Inhaled PCZ 10 mg: Inhaled Staccato Prochlorperazine 10 mg</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="93"/>
            <count group_id="B4" value="105"/>
            <count group_id="B5" value="400"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="103"/>
                    <measurement group_id="B5" value="395"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.0" spread="12.4"/>
                    <measurement group_id="B2" value="41.7" spread="11.8"/>
                    <measurement group_id="B3" value="42.9" spread="11.3"/>
                    <measurement group_id="B4" value="40.6" spread="12.1"/>
                    <measurement group_id="B5" value="41.8" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="85"/>
                    <measurement group_id="B5" value="349"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="105"/>
                    <measurement group_id="B5" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Headache Pain Relief at 2 hr</title>
        <description>Headache pain relief at 2 hr post-dose by IHS Definition (none=0 or mild=1),</description>
        <time_frame>2 hr post-dose</time_frame>
        <population>ITT w/ LOCF Population</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>Inhaled Staccato Placebo
Inhaled Placebo: Inhaled Staccato Placebo</description>
          </group>
          <group group_id="O2">
            <title>Inhaled PCZ 5 mg</title>
            <description>Inhaled Staccato Prochlorperazine 5 mg
Inhaled PCZ 5 mg: Inhaled Staccato Prochlorperazine 5 mg</description>
          </group>
          <group group_id="O3">
            <title>Inhaled PCZ 7.5 mg</title>
            <description>Inhaled Staccato Prochlorperazine 7.5 mg
Inhaled PCZ 7.5 mg: Inhaled Staccato Prochlorperazine 7.5 mg</description>
          </group>
          <group group_id="O4">
            <title>Inhaled PCZ 10 mg</title>
            <description>Inhaled Staccato Prochlorperazine 10 mg
Inhaled PCZ 10 mg: Inhaled Staccato Prochlorperazine 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Pain Relief at 2 hr</title>
          <description>Headache pain relief at 2 hr post-dose by IHS Definition (none=0 or mild=1),</description>
          <population>ITT w/ LOCF Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>Overall effect at 2 hr (by Cochran-Mantel-Haenszel) for TREATMENT</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responders, Pain-Free at 2 Hours</title>
        <description>Percentage of Responders, Pain-Free, by Treatment Group over Time</description>
        <time_frame>2 hours</time_frame>
        <population>ITT w/ LOCF Population</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>Inhaled Staccato Placebo
Inhaled Placebo: Inhaled Staccato Placebo</description>
          </group>
          <group group_id="O2">
            <title>Inhaled PCZ 5 mg</title>
            <description>Inhaled Staccato Prochlorperazine 5 mg
Inhaled PCZ 5 mg: Inhaled Staccato Prochlorperazine 5 mg</description>
          </group>
          <group group_id="O3">
            <title>Inhaled PCZ 7.5 mg</title>
            <description>Inhaled Staccato Prochlorperazine 7.5 mg
Inhaled PCZ 7.5 mg: Inhaled Staccato Prochlorperazine 7.5 mg</description>
          </group>
          <group group_id="O4">
            <title>Inhaled PCZ 10 mg</title>
            <description>Inhaled Staccato Prochlorperazine 10 mg
Inhaled PCZ 10 mg: Inhaled Staccato Prochlorperazine 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Responders, Pain-Free at 2 Hours</title>
          <description>Percentage of Responders, Pain-Free, by Treatment Group over Time</description>
          <population>ITT w/ LOCF Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="91"/>
                <count group_id="O4" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.281</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0226</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0019</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival of Headache Pain Relief</title>
        <description>Survival for time to the first successful headache pain relief by Pain-IHS definition over the 0 to 4 hr period by treatment assigned. Pairwise comparisons were made for each of the 3 active doses to placebo. Survival Analysis (Kaplan-Meyer) was included to evaluate treatment efficacy over the 0 to 4 hr period. All tests were 2-sided with a p-value at Î±=0.05.</description>
        <time_frame>0 to 4 hours</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Placebo</title>
            <description>Inhaled Staccato Placebo
Inhaled Placebo: Inhaled Staccato Placebo</description>
          </group>
          <group group_id="O2">
            <title>Inhaled PCZ 5 mg</title>
            <description>Inhaled Staccato Prochlorperazine 5 mg
Inhaled PCZ 5 mg: Inhaled Staccato Prochlorperazine 5 mg</description>
          </group>
          <group group_id="O3">
            <title>Inhaled PCZ 7.5 mg</title>
            <description>Inhaled Staccato Prochlorperazine 7.5 mg
Inhaled PCZ 7.5 mg: Inhaled Staccato Prochlorperazine 7.5 mg</description>
          </group>
          <group group_id="O4">
            <title>Inhaled PCZ 10 mg</title>
            <description>Inhaled Staccato Prochlorperazine 10 mg
Inhaled PCZ 10 mg: Inhaled Staccato Prochlorperazine 10 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Survival of Headache Pain Relief</title>
          <description>Survival for time to the first successful headache pain relief by Pain-IHS definition over the 0 to 4 hr period by treatment assigned. Pairwise comparisons were made for each of the 3 active doses to placebo. Survival Analysis (Kaplan-Meyer) was included to evaluate treatment efficacy over the 0 to 4 hr period. All tests were 2-sided with a p-value at Î±=0.05.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>Overall effect (0-4 hr) for TREATMENT by Log-rank p-value</p_value_desc>
            <method>Log Rank</method>
            <method_desc>There was no adjustment for multiple comparisons.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Log Rank</method>
            <method_desc>No adjustments were made for multiple comparisons</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From dosing (0 hours) through 24 hours</time_frame>
      <desc>Patient self- assessment for adverse events via Patient Diary over 0-24 hours at 7 specified time points</desc>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Placebo</title>
          <description>Inhaled Staccato Placebo
Inhaled Placebo: Inhaled Staccato Placebo</description>
        </group>
        <group group_id="E2">
          <title>Inhaled PCZ 5 mg</title>
          <description>Inhaled Staccato Prochlorperazine 5 mg
Inhaled PCZ 5 mg: Inhaled Staccato Prochlorperazine 5 mg</description>
        </group>
        <group group_id="E3">
          <title>Inhaled PCZ 7.5 mg</title>
          <description>Inhaled Staccato Prochlorperazine 7.5 mg
Inhaled PCZ 7.5 mg: Inhaled Staccato Prochlorperazine 7.5 mg</description>
        </group>
        <group group_id="E4">
          <title>Inhaled PCZ 10 mg</title>
          <description>Inhaled Staccato Prochlorperazine 10 mg
Inhaled PCZ 10 mg: Inhaled Staccato Prochlorperazine 10 mg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="104"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="91" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="104"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="93"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Psychiatric Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="104"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="93"/>
                <counts group_id="E4" events="32" subjects_affected="32" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="93"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="105"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="104"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="93"/>
                <counts group_id="E4" events="31" subjects_affected="31" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Executive VP, Research &amp; Development, Regulatory &amp; Quality</name_or_title>
      <organization>Alexza Pharmaceuticals, Inc</organization>
      <phone>650.944.7071</phone>
      <email>ClinicalTrialsInfo@alexza.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

